ALS網絡將支持協作研究工作

ALS網絡將在加利福尼亞州勞倫斯·利弗莫爾國家實驗室（Lawrence Livermore National Laboratory）上支持合作研究工作，該研究將使用電子健康記錄（EHRS）來確定可能減慢肌萎縮性側面硬化症（ALS）進展的現有藥物。

The ALS Network will be supporting a collaborative research effort, at California’s Lawrence Livermore National Laboratory, that will use electronic health records (EHRs) to identify existing medications that could slow the progression of amyotrophic lateral sclerosis (ALS).

ALS網絡將在加利福尼亞州勞倫斯·利弗莫爾國家實驗室（Lawrence Livermore National Laboratory）上支持一項合作研究工作，該研究將使用電子健康記錄（EHR）來確定可能減慢肌萎縮性側向硬化症（ALS）進展的現有藥物。

The $300,000 project is aimed at drug repurposing — finding medications already approved for other conditions that may have off-target effects beneficial in ALS. Because these therapies have well-established safety profiles, they could potentially be repurposed for use in ALS with less testing needed. That would allow these drugs to move more quickly through the development process for ALS than newly developed therapies.

這項耗資30萬美元的項目旨在重新使用藥物 - 發現已經批准了可能對ALS有益的其他靶向效果的藥物。由於這些療法具有完善的安全性概況，因此可能會重新使用用於較少測試的ALS。與新開發的療法相比，這將使這些藥物在ALS的開發過程中更快地移動。

The project will be led by Priyadip Ray, PhD, of Lawrence Livermore, as well as three other California-based researchers: Richard Reimer, MD, of Stanford University and Veterans Affairs; Jennifer Wilson, PhD, of the University of California, Los Angeles; and Kevin Grimes, MD, of Stanford University.

該項目將由勞倫斯·利弗莫爾（Lawrence Livermore）的Priyadip Ray博士領導，以及其他三名總部位於加利福尼亞的研究人員：斯坦福大學的理查德·雷默（Richard Reimer）和退伍軍人事務；加利福尼亞大學洛杉磯分校的詹妮弗·威爾遜（Jennifer Wilson）博士；斯坦福大學的醫學博士凱文·格萊姆斯（Kevin Grimes）。

“Medications typically have well-defined therapeutic targets, but often also have off-target effects,” Ray said in a press release from the ALS Network. “Our long-term goal is to identify associations between medications and progression of neurodegenerative diseases through the analysis of electronic health records. As an initial step, we have focused on ALS as a proof of principle study.”

雷在ALS網絡的新聞稿中說：“藥物通常具有明確定義的治療靶標，但通常也具有脫靶效應。” “我們的長期目標是通過分析電子健康記錄來確定藥物與神經退行性疾病的進展之間的關聯。作為第一步，我們將重點放在ALS上，作為主要研究的證明。”

Recommended Reading January 30, 2025 News by Andrea Lobo, PhD iPSC-derived microglia may help advance ALS research, therapies

推薦閱讀2025年1月30日，Andrea Lobo的新聞，博士IPSC衍生的小膠質細胞可能有助於推進ALS研究，療法

iPSC-derived microglia may help advance ALS research, therapies

IPSC衍生的小膠質細胞可能有助於進步ALS研究，療法

US nonprofit contributes $35K for drug-repurposing research

美國非營利組織為毒品替代研究貢獻了35,000美元

The ALS Network is providing about $35,000 in funding from its multifaceted research program for the study. Other funding will come from the ALS CURE Project, the Livermore Lab Foundation, the RDM Positive Impact Foundation, and Stanford University.

ALS網絡從其多面研究計劃中提供了約35,000美元的資金。其他資金將來自ALS Cure項目，Livermore Lab Foundation，RDM積極影響基金會和斯坦福大學。

“The ALS Network’s research-funding model is an ambitious program driven by urgency and innovation,” said Sheri Strahl, president and CEO of the ALS Network. “Providing funding to these experts will lead to greater discovery and progress critically needed to find better treatments and cures.”

ALS Network總裁兼首席執行官Sheri Strahl說：“ ALS網絡的研究資金模型是由緊迫性和創新驅動的雄心勃勃的計劃。” “向這些專家提供資金將導致更大的發現和進步，以找到更好的治療方法和治療方法。”

The collaborative project builds on a previous study that examined EHR data from more than 20,000 U.S. military veterans with ALS. Funded by the Livermore Lab Foundation with support from the ALS CURE Project, that research found several drugs and drug classes associated with longer survival in these patients.

該協作項目基於先前的研究，該研究檢查了來自ALS的20,000多名美國退伍軍人的EHR數據。由Livermore Lab Foundation資助，在ALS Cure項目的支持下，研究發現了幾種與這些患者生存期更長有關的藥物和藥物類別。

However, veterans have characteristics that differ significantly from the general population, the researchers noted. For example, they are mostly male and with military experience — both known risk factors for ALS — and this may prevent findings from being generalized to other ALS patient groups.

但是，研究人員指出，退伍軍人的特徵與普通人群有很大不同。例如，它們主要是男性，並且具有軍事經驗 - 兩者均是ALS的已知風險因素 - 這可能會阻止發現對其他ALS患者群體的推廣。

Providing funding to these experts will lead to greater discovery and progress critically needed to find better treatments and cures.

向這些專家提供資金將導致更大的發現和進步，以找到更好的治療方法和治療方法。

To address that, researchers will use the Optum EHR dataset to assess data from a more diverse population of patients. Access to the database will be provided by Stanford, with machine learning tools from the Lawrence Livermore National Laboratory used to scan through the data and find potential drug candidates.

為了解決這個問題，研究人員將使用optum EHR數據集評估來自更多患者人群的數據。斯坦福大學將提供對數據庫的訪問，並提供來自勞倫斯·利弗莫爾國家實驗室的機器學習工具，用於掃描數據並找到潛在的候選藥物。

While the initial focus is on ALS, the RDM Positive Impact Foundation will also support similar efforts in Parkinson’s disease. Once the research techniques are established in ALS, the team will apply them to the same Optum EHR dataset to look for drugs that may slow Parkinson’s progression.

儘管最初的重點是ALS，但RDM陽性影響基礎還將支持帕金森氏病的類似努力。一旦在ALS中建立了研究技術，該團隊將將它們應用於相同的optum EHR數據集，以尋找可能減慢帕金森氏症進展的藥物。

Ultimately, similarities across the two diseases may be used to accelerate the development of therapies for a broader range of neurodegenerative diseases, according to the researchers.

據研究人員稱，最終，兩種疾病之間的相似性可以用來加快針對更廣泛的神經退行性疾病的療法的發展。